Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP3082 in KRAS G12D Mutated NSCLC and PDAC
NCT07483983Phase 2Recruiting
- Sponsor
- Gustave Roussy
- Start
- Mar 2026
- Primary completion
- Sep 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
A Phase 2 trial of setidegrasib in non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), sponsored by Gustave Roussy. Started Mar 2026; status: recruiting.
02
Drugs
setidegrasib
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07483983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483983.